Cremieu Recoué, an independent researcher specializing in genetics, metrics, and demographics, joins MTS hosts Theo Jaffe and Gabriel Dickinson to discuss a dramatic shift in global biomedical innovation leadership.

The conversation reveals how China has rapidly overtaken the United States in clinical trial volume and novel drug development since implementing major regulatory reforms in 2016, fundamentally changing the landscape of pharmaceutical innovation.

The discussion covers China's systematic approach to streamlining clinical trials, their innovative market authorization systems, and strategic drug pricing negotiations that simultaneously lower costs while increasing pharmaceutical company profits.

China's Clinical Trial Dominance: The Numbers Behind the Shift

China now runs more clinical trials annually than the United States, surpassing America during COVID after starting from practically zero in 2016.

"We're more likely to have false positives and false negatives in our trials because they are smaller than theirs" - Cremieu, explaining how China's larger trial enrollments reduce statistical errors.

China leads in novel drug approvals and first-ever gene therapy trials, with 6x more novel gene therapies entering phase one than the US in 2025.

Chinese trials aren't just "Me Too" drugs copying existing treatments - they're targeting completely new therapeutic areas and novel mechanisms.

The 2016 Reform Revolution: How China Streamlined Drug Development

Before 2016, China's drug review process averaged 600+ days with six-year approval times, creating massive bureaucratic bottlenecks.

Post-2016 reforms introduced parallel ethics committees where one regional approval automatically applies to all trial sites nationally.

The Market Authorization Holder (MAH) system allows companies to maintain compliance records throughout trials with final audit only at completion, eliminating multiple review checkpoints.

China now accepts overseas clinical trial data from ICH member countries, requiring only basic assurance that treatments work in Chinese populations.

Review times dropped to 65-day targets with goals of reaching 40 days, compared to the previous 18+ month backlogs.

Strategic Drug Pricing: China's Win-Win Negotiation Model

"China says, well, no, we're going to make you profitable. We're actually going to make you money" - Cremieu describing China's unique approach to drug price negotiations.

Chinese negotiations simultaneously lower drug prices for consumers while increasing pharmaceutical company profits by dramatically expanding sales volumes.

This creates positive spillover effects with no negative impact on competing firms, unlike Western price negotiations that typically hurt pharmaceutical profits.

Areas targeted by Chinese price negotiations see the biggest increases in clinical trial activity, similar to how Medicare/Medicaid drove US innovation.

America's Innovation Funding Crisis and Path Forward

"Returns for pharmaceuticals are below the cost of capital" - Cremieu highlighting a fundamental problem with US pharmaceutical economics.

America's advantage comes from being "4% of the world's population, about 13% of all drug buying, but more than half of sales in dollar amounts."

Most Favored Nation (MFN) pricing policies threaten to further reduce pharmaceutical profits by matching peer country prices.

The FDA is implementing Bayesian methods and new approval pathways, but awareness problems prevent companies from utilizing available deregulation.

China allows germline gene therapy modifications affecting future generations, while the US maintains ethical restrictions on such treatments.